MedTrace Logo

Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

NCT03087019 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2022-10-14

Study results available
· View outcomes & findings →

Summary

This research study is studying immunotherapy with or without radiation therapy as a possible treatment for adenoid cystic carcinoma.

The immunotherapy involved in this study is:

* Pembrolizumab (MK-3475 or KEYTRUDA).

Conditions

  • Adenoid Cystic Carcinoma

Interventions

RADIATION

Radiation

Standard use of radiation is administered

DRUG

Pembrolizumab

Pembrolizumab is designed to restore the natural ability of the immune system to recognize and target cancer cells.

Sponsors & Collaborators

Principal Investigators

  • Jonathan Schoenfeld, MD, MPH · Dana-Farber Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-25
Primary Completion
2020-08-04
Completion
2020-08-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03087019 on ClinicalTrials.gov